Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

29 Sep 2011
by Working Group

Posted in Events, TB Drug Development, TB News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

ICAAC

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.

20 Sep 2011

TB R&D Weekly Update: Zinc Used by Host to Fight TB

CHM_covhighres

This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body’s immune response to intracellular infection by M.tb. and the microbe’s strategy to subvert this defense. Additional links to TB R&D news are included.

8 Sep 2011

TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry

fmccover

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.

30 Aug 2011
by Working Group

Posted in Front Lines of TB R&D, TB News

TB R&D Weekly Update: Future Medicinal Chemistry Features Neglected Diseases

fmccover

The August and September issues of Future Medicinal Chemistry will focus on neglected diseases including tuberculosis. The issue includes articles from TB researchers including Ann Ginsberg and Takushi Kaneko. Additional links to TB R&D news are included

16 Aug 2011
by Working Group

Posted in Front Lines of TB R&D, TB Drug Development

TB R&D Weekly Update: New Target Identified for Pyrazinamide

g-728

This week we highlight an article published out of Ying Zhang’s laboratory at Johns Hopkins University that puts forth a new model for the mode of action of pyrazinamide (PZA) and as well as suggest trans-translation as a potential target to consider in the development of new drugs for TB. Additional links to TB R&D news are included.

Updated WHO guidelines on Drug-Resistant TB

who-logo

The WHO issued updated guidelines on the programmatic management of drug-resistant TB on August 4, 2011 online in the European Respiratory Journal.

TB R&D Weekly Update: Some Multidrug-resistant Bacteria More Fit

bacteria

This week we have an article by researchers from Portugal that suggests that in the case of resistance conferred by plasmids that in some cases resistant bacteria increases its ability to replicate and overall fitness compared to susceptible bacteria. This may complicate research and control efforts to address the rising problem of multi-drug resistance. Additional links to TB R&D News are included.

TB R&D Weekly Update: Novel Compounds Screened for DS and MDR-TB

aaac cover_home

This week’s featured article from Bill Jacob’s lab looks at novel InhA (target of isoniazid (INH), a first-line TB drug) inhibitors and their ability to kill M. tuberculosis (M.tb) that is drug-sensitive, resistant and in dormant stage. Two compounds were identified that had significant bactericidal activity against M.tb: CD 39 and CD117. Additional links to TB R&D News are included.

TB R&D Weekly Update: P27-P55 Operon of Mtb and Drug Resistance

bmclogo

his week, we present an article from researchers from the Instituto de Biotecnologia and TB Control Program in Buenos Aires, Argentina. The article focuses on the P27-P55 operon which has been shown in mice to be essential for M. tuberculosis (M. tb) to survive in the host. Additional links to TB R&D news are included.

12 Jul 2011
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: Early bactericidal activity of OPC-67683

compound-OPC67683

This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity. Links to additional TB R&D news is included.